Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D gr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Proc Natl Acad Sci U S A
Päätekijät: Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Smith, Jordan L., Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2015
Aiheet:
PNAS Plus
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394293/
https://ncbi.nlm.nih.gov/pubmed/25805818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1415569112
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia